Related Experiment Video

Updated: Jan 23, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

Long noncoding RNA OR3A4 promotes cisplatin resistance of non-small cell lung cancer by upregulating CDK1

J Shang1, Y-D Xu, Y-Y Zhang

  • 1Department of Central Sterile Supply, Yantai Yuhuangding Hospital, Yantai, China. YSLM0142@outlook.com.

European Review for Medical and Pharmacological Sciences
|June 8, 2019
PubMed
Abstract

Insights

Long non-coding RNA OR3A4 promotes cisplatin resistance in non-small cell lung cancer (NSCLC) by upregulating CDK1. Silencing OR3A4 reverses resistance, offering a potential therapeutic target for NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) play a critical role in various cancers, including non-small cell lung cancer (NSCLC).
  • Understanding the specific functions of lncRNAs in drug resistance is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the role of lncRNA olfactory receptor family 3 subfamily A member 4 (OR3A4) in cisplatin resistance in NSCLC.
  • To explore the underlying molecular mechanisms by which OR3A4 influences cisplatin sensitivity.

Main Methods:

  • Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) was used to measure OR3A4 expression levels.
  • Cell Counting Kit-8 (CCK-8) and flow cytometry were employed to assess the functional impact of OR3A4 on NSCLC cell viability and apoptosis.
  • Mechanism assays were performed to elucidate the molecular pathways involved.

Main Results:

  • OR3A4 expression was significantly higher in cisplatin-resistant NSCLC cells (A549/DDP) compared to sensitive cells (A549).
  • Silencing OR3A4 in A549/DDP cells induced cell cycle arrest and apoptosis, and reversed cisplatin resistance.
  • Knockdown of OR3A4 led to the suppression of CDK1 expression in resistant NSCLC cells.

Conclusions:

  • OR3A4 promotes cisplatin resistance in NSCLC by upregulating CDK1, affecting cell cycle and apoptosis.
  • OR3A4 represents a potential therapeutic target for overcoming cisplatin resistance in non-small cell lung cancer patients.

More Related Videos

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.4K
Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data07:35

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data

Published on: December 1, 2023

1.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
The Eukaryotic Promoter Region02:40

The Eukaryotic Promoter Region

The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences.  The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
18.7K
RNA Polymerase II Accessory Proteins02:36

RNA Polymerase II Accessory Proteins

Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...
10.8K
Bacterial RNA Polymerase00:43

Bacterial RNA Polymerase

Unlike eukaryotes, bacteria use a single RNA Polymerase (RNAP) to transcribe all genes. The different subunits of bacterial RNAPhave distinct functions. The multisubunit structure of the bacterial RNAP helps the enzyme to maintain catalytic function, facilitate assembly, interact with DNA and RNA, and self-regulate its activity.
In most genes, the transcription site is a single base present upstream of the coding sequence. Though RNAP is a catalytically efficient enzyme, it does not recognize...
32.6K
Eukaryotic RNA Polymerases00:58

Eukaryotic RNA Polymerases

RNA Polymerase (RNAP) is conserved in all animals, with bacterial, archaeal, and eukaryotic RNAPs sharing significant sequence, structural, and functional similarities. Among the three eukaryotic RNAPs, RNA Polymerase II is most similar to bacterial RNAP in terms of both structural organization and folding topologies of the enzyme subunits. However, these similarities are not reflected in their mechanism of action.
All three eukaryotic RNAPs require specific transcription factors, of which the...
26.8K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K